文 | 卿照九源基因正迎来上市后的持续尴尬。上市当天就破发,此后持续下跌,如今已经只有发行价的一半。遭遇如此的看低,有许多因素共同促成。比如全球经济环境和资本市场波动性加剧,导致投资者对新股的风险偏好下降。此外,港股医疗器械企业正处于历史低值时期。但不可否认的是,九源基因的业务基本面中,如今并未有太多闪光点。即便是有减肥药的研发来“帮帮场子”,也无法能真正吸引投资者的关注目光。减肥药故事好讲不好做...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.